Skip to main content

About iQ&A T2D and CV Outcomes

The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor..

The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period March 15, 2017 through March 15, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 115 segments, totaling 3 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

3.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to improve the management of Type 2 diabetes.

Release Date

March 15, 2017

Expiration Date

March 15, 2019

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for Type 2 diabetes..

Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Rheumatoid Arthritis is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This activity is supported by an independent medical education grant from Novo Nordisk

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials. 

Program Faculty and Disclosure

Program Faculty and Disclosure
Vivian Fonseca, MD – Program Chair
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association

Research Support (to Tulane): Novo Nordisk, Asahi, Eli Lilly, Abbott, Endo Barrier, Gilead Sciences
Honoraria for Consulting and Lectures: Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Pamlabs, AstraZeneca, Abbott, Amgen, Boehringer Ingelheim, Janssen


Steve Bain, MD
Professor of Medicine (Diabetes)
College of Medicine
Swansea University
Swansea, UK

Nothing to disclose

Jaime Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical School
Dallas, TX

Advisor or Consultant: Amgen Inc.; Aspire Bariatrics; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; LifeScan, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk; REMD Bio; Sanofi
Speaker: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals, Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.


Ralph DeFronzo, MD
Professor of Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, TX

Consulting: AstraZeneca, Janssen, Intarcia, Novo Nordisk
Fees for Non-CME/CE Services: AstraZeneca, Novo Nordisk
Ownership Interest (Stocks, stock options, etc): AstraZeneca, Janssen


Stefano Del Prato, MD PhD
Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
University of Pisa, Italy
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, TX

Consulting: Novo Nordisk, Boehringer-Ingelheim, Lilly, Pfizer, Sanofi
Speaker’s Bureau: Novo Nordisk, Merck, AstraZeneca, Janssen


Juan P. Frias, MD, FACE
Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California

Consulting Fees: Johnson and Johnson, Astra Zeneca, Sanofi
Contracted Research: Astra Zeneca, Boehringer Ingelheim, BMS, Lilly, Novo Nordisk, Merck, Pfizer, Sanofi


Luc Van Gaal, MD
Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium

Nothing to disclose

Robert Henry, MD
Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego

Advisor or consultant: Alere; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc; Elcelyx Therapeutics, Inc; Ionis Pharmaceuticals; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, LLC; Novo Nordisk; Sanofi
Grants/Research Support: AstaReal; Boehringer Ingelheim Pharmaceuticals, Inc; Hitachi; Lexicon Pharmaceuticals, Inc.; Lilly; Novo Nordisk; REMD Biotherapeutics; ViaCyte, Inc


Serge A. Jabbour, MD, FACP, FACE
Professor of Medicine
Thomas Jefferson University
Division of Endocrinology, Diabetes and Metabolic Diseases
Department of Medicine
Jefferson Medical College
Philadelphia, Pennsylvania

Consulting: AstraZeneca, Johnson & Johnson, Lilly and Boehringer-Ingelheim
Fees for Non-CME/CE Services: AstraZeneca, Johnson & Johnson, Lilly

Lawrence A. Leiter, MD, FRCP(C), FACP
Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor, Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario
Canada

Consulting: Astra Zeneca, BI, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier
Speakers Bureau: Astra Zeneca, BI, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi
Contracted Research: Astra Zeneca, BI, Eli Lilly, GSK, Janssen, Merck, Novo Nordisk, Pfizer, Sanofi, Servier


Johannes F.E. Mann, MD
Professor of Medicine
University of Erlangen-Nürnberg
Director, Dept. of Nephrology, Hypertension & Rheumatology
Munich General Hospitals
Munich, Germany

Nothing to disclose
Chantal Mathieu, MD, PhD
Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium

Advisory Board, Research Support, and Speaker: Novo Nordisk, Medtronic, Roche, Sanofi, Boehringer Ingelheim, AstraZeneca


John Petrie, MD, PhD
Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland

Nothing to disclose


Richard Pratley, MD
Senior Investigator
Translational Research Institute for Metabolism and Diabetes
Medical Director, Florida Hospital Diabetes Institute (FHDI)
Professor, Sanford-Burnham Medical Research Institute at Lake Nona
Orlando, Florida

Contracted Research: Novo Nordisk, Merck, Sanofi, Lexicon, Lilly

Itamar Raz, MD
Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel

Consulting: AstraZeneca, Eli Lilly

Josep Vidal, MD, PhD
 Obesity Unit, Endocrinology and Diabetes Unit
University Hospital Clinic
Barcelona, Spain

Nothing to disclose

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.


Educational Objectives

Upon completion of this activity, participants will be able to: Compare and contrast the various technologies used to detect actionable mutational targets in cancer

  • Identify T2D patients in whom the possible advantages of incretin system-targeted therapy with GLP-1 RAs may confer reduction in CV risk
  • Individualize multimodal, pharmacologic management in patients with T2D, and improve patient outcomes by deploying combination regimens that act through multiple, complementary mechanisms—including long- and ultra-long acting insulin and incretin system-targeted interventions, to optimize glycemic control and CV risk reduction
  • Explain the physiologic basis for when, why, and in which patients subgroups a long- or ultra-long acting insulin, alone or in combination with a GLP-1 RA is appropriate and is likely to improve HA1c target goal attainment and/or cardiovascular disease (CVD) risk reduction in patients with diabetes;
  • Become more clinically proficient at titrating the dose(s) of both long-acting insulin and a GLP-1 agonist, when used separately or in combination insulin-plus-GLP-1 RA formulations, to achieve HA1c target goal, weight loss, reduction in risk of hypoglycemia, and CV risk reduction
  • Describe how fixed dose combination therapies employing a GLP-1 RA and long-acting insulin can provide complementary efficacy, especially in patients who require mitigating risk of hypoglycemia or more effective glycemic control


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Disclaimer

Copyright © 2017 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC
ABOUT THIS PROGRAM AND FACULTY DISCLOSURES
GLYCEMIC CONTROL-FOCUSED RESOURCES AND CLINICAL TRIALS